Strong first quarter launchpad for Valeant rebranding exercise

8 May 2018

Troubled Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) got a shot of good news in morning trading, as investors reacted warmly to a positive first quarter 2018 financial results statement.

In New York, shares of the company were trading around a tenth higher at lunchtime, after the firm announced revenues of $1.9 billion, down from $2.1 billion in the same period last year, but a little above the Financial Times’ consensus forecast.

Following Generally Accepted Accounting Principles (GAAP), the firm reported a $2.6 billion loss due to write-offs of $2.2 billion related its Salix and Ortho Dermatologics businesses. This equates to an earnings per share figure of negative $7.68.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK